1. P14.122 Integrin α5 is a poor prognostic factor in patients with glioblastoma treated by the Stupp protocol. (6th September 2019) Authors: Etienne-Selloum, N; Prades, J; Bello Roufai, D; El Azumi, F; Boone, M; Sevestre, H; Trudel, S; Coutte, A; Desenclos, C; Constans, J; Chauffert, B; Dontenwill, M Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 3 Page Start: iii97 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P14.125 Retrospective analysis of long-term response to bevacizumab in combination with irinotecan for recurrent glioblastoma: identification of prognostic factors. (6th September 2019) Authors: Besson, C; Morisse, M; Brut, H; Waissi, W; Noel, G; Chauffert, B; Prébay, D; Schott, R; Etienne-Selloum, N Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 3 Page Start: iii98 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P14.92 Study of Glutaminergic and Glutamatergic Metabolism in 1H-MRS Monovoxel in the Most Aggressive Part of 62 Glioblastoma Before and After 18 months Treatment. (6th September 2019) Authors: Heintz, A; Chombar, J; Boussida, S; Saidak, Z; Lefranc, M; Deleval, N; Coutte, A; Chauffert, B; Boone, M; Constans, J Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 3 Page Start: iii89 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗